A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced by ‘on-target/off-tumor’ binding to PD-L1 widely...

書誌詳細
出版年:	OncoImmunology
主要な著者:	Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer, Wijnand Helfrich
フォーマット:	論文
言語:	英語
出版事項:	Taylor & Francis Group 2018-08-01
主題:	bispecific antibody egfr immunotherapy pd-l1
オンライン･アクセス:	http://dx.doi.org/10.1080/2162402X.2018.1466016

類似資料

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
著者:: Mark A. J. M. Hendriks, 等
出版事項: (2020-01-01)

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
著者:: Fuxin Xue, 等
出版事項: (2024-10-01)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
著者:: Lennart Kühl, 等
出版事項: (2023-12-01)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
著者:: Laura Rubio-Pérez, 等
出版事項: (2023-12-01)

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells
著者:: Vinicio Melo, 等
出版事項: (2023-07-01)

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
著者:: Arturo Simoni-Nieves, 等
出版事項: (2024-09-01)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
著者:: Mengke Niu, 等
出版事項: (2023-08-01)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
著者:: Nishant Mohan, 等
出版事項: (2022-06-01)

Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
著者:: Junjun Fu, 等
出版事項: (2023-03-01)

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
著者:: Tianye Li, 等
出版事項: (2024-03-01)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
著者:: Nami Tateyama, 等
出版事項: (2022-11-01)

Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer
著者:: Rui Cao, 等
出版事項: (2019-02-01)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
著者:: Johannes Sam, 等
出版事項: (2020-11-01)

CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways
著者:: Michael B. Murphy, 等
出版事項: (2023-07-01)

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
著者:: Weishi Cheng, 等
出版事項: (2024-07-01)

Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1
著者:: Julia Harwardt, 等
出版事項: (2024-05-01)

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
著者:: Przemysław Bielski, 等
出版事項: (2025-05-01)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
著者:: Manley T. F. Huang, 等
出版事項: (2022-12-01)

Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
著者:: Lauren C. Naatz, 等
出版事項: (2025-03-01)

Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody
著者:: Shi Hu
出版事項: (2017-05-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
著者:: Ammelie Svea Boje, 等
出版事項: (2024-12-01)

Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody
著者:: Ming Yi, 等
出版事項: (2024-11-01)

A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
著者:: Qi Song, 等
出版事項: (2024-11-01)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
著者:: Ning Shi, 等
出版事項: (2022-11-01)

Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1
著者:: Perrine Jacquot, 等
出版事項: (2023-03-01)

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
著者:: Alan W Long, 等
出版事項: (2024-04-01)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
著者:: Mark A.J.M. Hendriks, 等
出版事項: (2021-01-01)

PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis
著者:: Lauren C. Naatz, 等
出版事項: (2025-08-01)

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
著者:: Shuai Hao, 等
出版事項: (2022-10-01)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
著者:: Tianye Li, 等
出版事項: (2023-07-01)

Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
著者:: Yang Xiao, 等
出版事項: (2021-01-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
著者:: Yilin Wang, 等
出版事項: (2025-04-01)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
著者:: Pauline Malinge, 等
出版事項: (2024-12-01)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
著者:: Xinghua Pang, 等
出版事項: (2023-12-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
著者:: Yaofei Jiang, 等
出版事項: (2025-03-01)

Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery
著者:: Artem S. Grevtsev, 等
出版事項: (2023-12-01)

Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
著者:: Weimin Chen, 等
出版事項: (2021-01-01)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
著者:: Hao Zhang, 等
出版事項: (2023-09-01)

The eIg technology to generate Ig-like bispecific antibodies
著者:: Lennart Kühl, 等
出版事項: (2022-12-01)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
著者:: Qingyun Yuan, 等
出版事項: (2021-01-01)